Organoids are three-dimensional (3D) in vitro tissue models that are derived from stem cells and can closely mimic the structure and function of human organs. The ability to create organoids that recapitulate the complex cellular architecture of organs has emerged as an innovative technique in biomedical research and drug development. However, traditional methods of organoid culture are time consuming and often yield low quantities of cells, which has led to the development of 3D bioprinting of organoids from bioinks containing suspended cells and desired scaffolds. A comparison across different organoid-building techniques, focusing on 3D bioprinting and its benefits, may be helpful and was yet to be distinguished. The goal of this review is to provide an overview of the current state of 3D bioprinting of organoids and its potential applications in tissue engineering, drug screening, and regenerative medicine.
Impact statement
The potential benefits of three-dimensional (3D) bioprinted organoids are significant, and as the technology continues to evolve, we can expect to see more applications in disease modeling, drug discovery, and regenerative medicine. However, there are still several challenges that need to be addressed before 3D bioprinted organoids can be routinely used in the clinic. Nonetheless, the future of 3D bioprinting of organoids is exciting, and it has the potential to revolutionize the field of tissue engineering and regenerative medicine.
Get full access to this article
View all access options for this article.
References
1.
SimianM, BissellMJ. Organoids: A historical perspective of thinking in three dimensions. J Cell Biol, 2017; 216(1):31–40; doi: 10.1083/jcb.201610056
2.
CacciamaliA, VillaR, DottiS. 3D cell cultures: Evolution of an ancient tool for new applications. Front Physiol, 2022; 13:836480; doi: 10.3389/fphys.2022.836480
3.
LanghansSA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol, 2018; 9:6; doi: 10.3389/fphar.2018.00006
4.
VioletaCarvalho, ManuelBañobre-López, GraçaMinas, et al.The integration of spheroids and organoids into organ-on-a-chip platforms for tumour research: A review. Bioprinting, 2022; 27:e00224; doi: 10.1016/j.bprint.2022.e00224
5.
GuntiS, HokeATK, VuKP, et al.Organoid and spheroid tumor models: Techniques and applications. Cancers (Basel), 2021; 13(4):874; doi: 10.3390/cancers13040874
6.
FangG, ChenY-C, LuH, et al.Advances in spheroids and organoids on a chip. Adv Funct Mater, 2023; 33(19):2215043; doi: 10.1002/adfm.202215043
7.
GuZ, FuJ, LinH, et al.Development of 3D bioprinting: From printing methods to biomedical applications. Asian J Pharm Sci, 2020; 15(5):529–557; doi: 10.1016/j.ajps.2019.11.003
8.
DeyM, OzbolatIT. 3D bioprinting of cells, tissues and organs. Sci Rep, 2020; 10(1):14023; doi: 10.1038/s41598-020-70086-y
9.
LvD, HuZ, LuL, et al.Three-dimensional cell culture: A powerful tool in tumor research and drug discovery. Oncol Lett, 2017; 14(6):6999–7010; doi: 10.3892/ol.2017.7134
10.
KoledovaZ. 3D cell culture: An introduction. Methods Mol Biol, 2017; 1612:1–11; doi: 10.1007/978-1-4939-7021-6_1
11.
LarsonB.3D Cell Culture: A Review of Current Techniques. BioTek Instruments, Inc.: Winooski, VT, USA; 2021.
12.
RenY, YangX, MaZ, et al.Developments and opportunities for 3D bioprinted organoids. Int J Bioprint, 2021; 7(3):364; doi: 10.18063/ijb.v7i3.364
13.
PariharA, PanditaV, KhanR. 3D printed human organoids: High throughput system for drug screening and testing in current COVID-19 pandemic. Biotechnol Bioeng, 2022; 119(10):2669–2688; doi: 10.1002/bit.28166
14.
FongEL, Lamhamedi-CherradiSE, BurdettE, et al.Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc Natl Acad Sci U S A, 2013; 110(16):6500–6505; doi: 10.1073/pnas.1221403110
15.
HongZX, ZhuST, LiH, et al.Bioengineered skin organoids: From development to applications. Mil Med Res, 2023; 10(1):40; doi: 10.1186/s40779-023-00475-7
16.
LancasterMA, RennerM, MartinCA, et al.Cerebral organoids model human brain development and microcephaly. Nature, 2013; 501(7467):373–379; doi: 10.1038/nature12517
17.
UrbaniakA, ReedMR, FilD, et al.Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models. Biomed Pharmacother, 2021; 141:111815; doi: 10.1016/j.biopha.2021.111815
18.
SchusterB, JunkinM, KashafSS, et al.Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun, 2020; 11(1):5271; doi: 10.1038/s41467-020-19058-4
19.
AuSH, ChamberlainMD, MaheshS, et al.Hepatic organoids for microfluidic drug screening. Lab Chip, 2014; 14(17):3290–3299; doi: 10.1039/c4lc00531g
20.
Tomaskovic-CrookE, HigginbottomSL, ZhangB, et al.Defined, simplified, scalable, and clinically compatible hydrogel-based production of human brain organoids. Organoids, 2023; 2(1):20–36; doi: 10.3390/organoids2010002
21.
YuJ, ParkSA, KimWD, et al.Current advances in 3D bioprinting technology and its applications for tissue engineering. Polymers (Basel), 2020; 12(12):2958; doi: 10.3390/polym12122958
22.
LandersR, HubnerU, SchmelzeisenR, et al.Rapid prototyping of scaffolds derived from thermoreversible hydrogels and tailored for applications in tissue engineering. Biomaterials, 2002; 23:4437–4447; doi: 10.1016/s0142-9612(02)00139-4
23.
ZhuangX, DengG, WuX, et al.Recent advances of three-dimensional bioprinting technology in hepato-pancreato-biliary cancer models. Front Oncol, 2023; 13:1143600; doi: 10.3389/fonc.2023.1143600
24.
GillispieG, PrimP, CopusJ, et al.Assessment methodologies for extrusion-based bioink printability. Biofabrication, 2020; 12(2):022003; doi: 10.1088/1758-5090/ab6f0d
25.
OzbolatIT, HospodiukM. Current advances and future perspectives in extrusion-based bioprinting. Biomaterials, 2016; 76:321–343; doi: 10.1016/j.biomaterials.2015.10.076
26.
FangY, GuoY, LiuT, et al.Advances in 3D bioprinting. Chin J Mech Eng Addit Manuf Front, 2022; 1(1):100011; doi: 10.1016/j.cjmeam.2022.100011
27.
JamiesonC, KeenanP, KirkwoodD, et al.A review of recent advances in 3D bioprinting with an eye on future regenerative therapies in veterinary medicine. Front Vet Sci, 2020; 7:584193; doi: 10.3389/fvets.2020.584193
28.
TakagiD, LinW, MatsumotoT, et al.High-precision three-dimensional inkjet technology for live cell bioprinting. Int J Bioprint, 2019; 5(2):208; doi: 10.18063/ijb.v5i2.208
29.
LeonovDV, SpirinaYA, YatsenkoAA, et al.Advanced 3D bioprinting technologies. Cell Tissue Biol, 2021; 15:616–627; doi: 10.1134/S1990519X21060134
30.
LeeH. Engineering in vitro models: Bioprinting of organoids with artificial intelligence. Cyborg Bionic Syst, 2023; 4:0018; doi: 10.34133/cbsystems.0018
31.
BaiL, WuY, LiG, et al.AI-enabled organoids: Construction, analysis, and application. Bioact Mater, 2024; 31:525–548; doi: 10.1016/j.bioactmat.2023.09.005
32.
ChenH, WuZ, GongZ, et al.Acoustic bioprinting of patient-derived organoids for predicting cancer therapy responses. Adv Healthc Mater, 2022; 11(13):e2102784; doi: 10.1002/adhm.202102784
33.
BertassoniLE, CardosoJC, ManoharanV, et al.Direct-write bioprinting of cell-laden methacrylated gelatin hydrogels. Biofabrication, 2014; 6(2):024105; doi: 10.1088/1758-5082/6/2/024105
34.
BrassardJA, NikolaevM, HubscherT, et al.Recapitulating macro-scale tissue self-organization through organoid bioprinting. Nat Mater, 2021; 20(1):22–29; doi: 10.1038/s41563-020-00803-5
35.
AlhaqueS, ThemisM, RashidiH. Three-dimensional cell culture: From evolution to revolution. Philos Trans R Soc Lond B Biol Sci, 2018; 373(1750):20170216; doi: 10.1098/rstb.2017.0216
36.
MaoS, HeJ, ZhaoY, et al.Bioprinting of patient-derived in vitro intrahepatic cholangiocarcinoma tumor model: Establishment, evaluation and anti-cancer drug testing. Biofabrication, 2020; 12(4):045014; doi: 10.1088/1758-5090/aba0c3
37.
PapaspyropoulosA, TsolakiM, ForoglouN, et al.Modeling and targeting Alzheimer's disease with organoids. Front Pharmacol, 2020; 11:396; doi: 10.3389/fphar.2020.00396
38.
ZhangY, ChenH, LongX, et al.Three-dimensional-engineered bioprinted in vitro human neural stem cell self-assembling culture model constructs of Alzheimer's disease. Bioact Mater, 2022; 11:192–205; doi: 10.1016/j.bioactmat.2021.09.023
39.
GerbolésAG, GalettiM, RossiS, et al.Three-dimensional bioprinting of organoid-based scaffolds (OBST) for long-term nanoparticle toxicology investigation. Int J Mol Sci, 2023; 24(7):6595; doi: 10.3390/ijms24076595
40.
XieF, SunL, PangY, et al.Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine. Biomaterials, 2021; 265:120416; doi: 10.1016/j.biomaterials.2020.120416
41.
KangHW, LeeSJ, KoIK, et al.A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol, 2016; 34(3):312–319; doi: 10.1038/nbt.3413
42.
BernalPN, BouwmeesterM, Madrid-WolffJ, et al.Volumetric bioprinting of organoids and optically tuned hydrogels to build liver-like metabolic biofactories. Adv Mater, 2022; 34(15):e2110054; doi: 10.1002/adma.202110054
